Alcor Review: The Logic of Biological Continuity and the Temporal Safety-Net Unhack

A hospital monitor flatlines, a doctor says the words, and in the version of events you’ve always accepted, that’s the end of the story. But somewhere in Scottsdale, Arizona, an organisation has spent fifty years operating on a different assumption: that the seconds after “time of death” are not a full stop but a deadline — and that what happens in the next few hours decides whether a person is gone or merely paused. Whether they’re right is one of the most genuinely uncertain bets a human can make.

The short version: Alcor is a non-profit cryonics provider, operating since 1972, that preserves legally deceased members in liquid nitrogen on the speculative bet that future medicine could repair and revive them. Per Alcor’s own published schedule, the minimum funding is $80,000 for neuro-preservation (brain only) and $200,000 for whole body — not the half-million figures often quoted — usually arranged through life insurance rather than cash. Its distinctive strengths are aligned incentives (board members are required to be members themselves), published case reports, and decades of legal standing. But no human has ever been revived from cryopreservation, no method for doing so exists, and the procedure begins only after a physician has pronounced legal death. This is a long-odds wager, not a medical service.

What Alcor is, and why “death as a pause” is its founding bet

You’ve been told death is final. Alcor’s premise is that legal death (heart stoppage) happens well before biological death (irreversible destruction of the brain’s structure), and that the gap between them is a rescue interval.

The reasoning runs like this: if your connectome — the pattern of neural connections that encodes your mind — survives intact, then some future technology (molecular repair, high-resolution scanning, or emulation) might theoretically restore you. Alcor has operated on that assumption since 1972, using vitrification chemistry developed in part by 21st Century Medicine — principally the M22 solution from the work of Gregory Fahy and Brian Wowk — to replace blood with cryoprotectant compounds that aim to prevent ice-crystal damage at −196°C. The chemistry is real, but it isn’t benign: cryobiologists broadly agree that cryoprotectant toxicity is the central unsolved limit on reversible organ cryopreservation, and M22 reduces that toxicity rather than removing it. Vitrification also doesn’t rule out other injury — osmotic stress, incomplete perfusion where circulation was already compromised before cooling began, and fracturing at deep cryogenic temperatures.

Here’s the reframe that organises everything Alcor does: a cremated or buried brain has a structurally guaranteed zero chance of any future; a preserved one has an unknown, unproven, non-zero one. That is the entire bet, and it’s important to state its honesty plainly — Alcor has roughly 250 patients in storage and around 1,450 paying cryopreservation members (Alcor’s own membership statistics, updated periodically), and it publishes technical case reports including failures — but not a single revival, and not a single attempt at one. The transparency is real; the success rate is, so far, undemonstrated.

How Alcor actually works: the Standby, Stabilization, Transport stack

The whole operation lives or dies on speed — once the heart stops, hypoxic brain damage becomes a clock. Alcor’s workflow:

• Medical standby team: you register and carry a membership alert card; if you’re dying or hospitalised, you notify Alcor and they deploy a team, coordinating with local funeral directors and medical staff.
• Immediate stabilisation: the team begins cardiopulmonary support and cools the body rapidly using ice and cold saline, slowing cellular metabolism to buy time before vitrification.
• Transport to Scottsdale, AZ: the patient travels to Alcor’s facility under continuous care.
• Vitrification protocol: over a period of hours, blood is gradually replaced with M22 cryoprotectant, intended to prevent the ice-crystal formation that would destroy cell structures. Perfusion times and quality vary considerably from case to case — that variation is visible in Alcor’s published case reports, and it is the single biggest determinant of how well a given patient is actually preserved.
• Long-term storage: the body (whole-body) or brain (neuro) is cooled to −196°C in a liquid-nitrogen dewar. The dewars are passive vacuum vessels, not powered freezers, so a power cut doesn’t warm them; by Alcor’s own dewar-maintenance estimate, it would take more than 90 days to boil dry if liquid-nitrogen resupply stopped entirely.

Neuro vs whole-body: why brain-only is Alcor’s signature

Alcor offers two preservation options, and the price gap is steep. These are minimum funding figures from Alcor’s published schedule, not estimates:

• Neuro-preservation — $80,000 minimum: brain and upper cervical spine only. The case for it: smaller volume means more uniform vitrification, more aggressive cooling, and lower storage cost — on the assumption that future technology could grow or synthesise a new body from the preserved connectome.
• Whole-body preservation — $200,000 minimum: the entire body, preserving peripheral organs and nervous system, as a hedge in case whole-body regeneration turns out to be the more tractable path.

Two things inflate those headline numbers in practice. Funding $20,000 above either minimum ($100,000 neuro, $220,000 whole body) permanently waives the annual Comprehensive Member Standby fee, and most members take that option. And surcharges apply for cases outside the US and Canada (+$10,000), for anyone needing service within 180 days of joining (+$20,000), and for non-members arranged by third parties (+$50,000). So the realistic range is roughly $100,000 to $270,000 depending on option and circumstances — still well under the half-million figure that circulates online.

Neuro is Alcor’s signature because, in its framing, identity lives in synaptic patterns rather than the skeleton. Whether that framing is correct is, again, an open question riding on a future no one can verify — so treat the neuro/whole-body choice as a bet within a bet.

The economic durability problem: why Alcor is built to outlive itself

The sharpest fear: what if Alcor goes bankrupt? The body thaws, the brain degrades, the preservation is wasted.

Alcor’s answer is the Patient Care Trust — a legally separate endowment in conservative assets, dedicated solely to long-term patient maintenance, funded by allocating a defined share of each member’s preservation payment. It’s structured so that even if Alcor the operating organisation fails, the Trust keeps paying for dewar maintenance, nitrogen, and monitoring, and it can’t be seized to cover Alcor’s operating debts. On size: the most recent figure Alcor has published puts the combined Patient Care Trust and Alcor Care Trust assets at about $17.98 million as of 31 December 2019. Later totals aren’t publicly posted, so anyone quoting a current number — including a “$20 million+” figure — is extrapolating, not citing.

The fear is not hypothetical, either. In 1979 the Cryonics Society of California abandoned its Chatsworth vault, and roughly nine patients thawed and decomposed when funding and attention ran out — the case that gave the field its trust-fund architecture. Alcor’s own history has been contentious rather than placid: the 1988 Dora Kent coroner’s raid, the Ted Williams family dispute, and Alcor v. Richardson all reached courts (case history). No Alcor patient is known to have been lost to a funding failure — but “no financial crisis in 54 years” overstates a record that has included real institutional stress.

The honest caveat: this structure is genuinely robust by the standards of any organisation — but the bet requires institutional survival across a century or more, a timescale on which no track record can offer real assurance. The Trust lowers the risk; it cannot remove it.

The aligned-incentive logic: staff are also patients

Here’s the genuinely unusual part, and it’s structural rather than cultural: Alcor’s bylaws require every member of its Board of Directors to be an Alcor member, and all five trustees of the Alcor Care Trust must be Cryopreservation Members (membership FAQ). The people governing your suspension and the endowment that pays for it intend to be in the same vault someday. Whether every staff member holds a contract isn’t something Alcor publishes, so treat the broader “everyone who works there is signed up” version as unverified.

This is extreme skin-in-the-game alignment — you’re not a customer being sold a service so much as a logistical peer in a shared, uncertain mission. It’s the most reassuring structural feature Alcor has: the operators carry the same downside you do. It doesn’t make revival more likely, but it does make neglect far less likely, and on a multi-decade preservation that distinction matters.

The revival challenge: how would an Alcor patient actually come back?

This is the hard, honest core: revival is speculative, and current science has no working roadmap. The plausible theories on offer:

• Whole-Brain Emulation (WBE): high-resolution scanning of the preserved connectome, mapped onto a computer or synthetic neural substrate, so the “mind” runs digitally or in a synthetic body.
• Molecular repair: nanotechnology or advanced biotech repairs vitrification damage and restores the brain to working condition.
• Hybrid revival: partial biological restoration plus partial digital emulation, depending on what’s possible.

None of these exists. No human, and no large mammal, has ever been revived from cryopreservation; there is no experimental protocol that anyone claims would do it. Alcor’s position is that preserving the connectome now maximises future options — a degraded brain has zero paths, a preserved one has several speculative ones. That’s a defensible philosophical stance, but it is a stance, not a demonstrated outcome, and no honest reading should blur the two.

Even-handedness cuts the other way too, though, because “the science is going nowhere” is also false. In 2023 a University of Minnesota team vitrified rat kidneys, stored them cryogenically for up to 100 days, rewarmed them using iron-nanoparticle “nanowarming”, and transplanted them back into rats where they restored life-sustaining renal function — the first repeatable recovery of a life-supporting mammalian organ from cryogenic storage. And in 2018 the Brain Preservation Foundation awarded its Large Mammal Prize for demonstrating preserved synaptic connectivity across an entire pig brain, verified by 3D electron microscopy. Read those honestly: a kidney is not a brain, and the pig-brain method (aldehyde-stabilised cryopreservation) uses chemical fixation that Alcor does not use, so neither result validates Alcor’s specific protocol and neither is a revival. What they show is that preservation quality is a real research frontier with real results. What still doesn’t exist, anywhere, is a method for restoring a preserved human.

How to join Alcor: membership and funding mechanics

1. Apply for membership at Alcor.org, answering health questions. Alcor doesn’t publish a guaranteed review turnaround, so treat any specific timeline you see quoted as an estimate rather than a commitment. Dues are neither free nor flat: Alcor uses age-based dues, calculated as your age when you sign multiplied by an annual dues multiplier ($15 in 2025, reviewed annually by the board). A 30-year-old therefore pays about $450/year and a 50-year-old about $750/year, with $200/year for 18-year-olds and $60/year per minor child. There is also a separate annual Comprehensive Member Standby fee, waivable permanently by funding $20,000 above the minimum. The preservation contract is still the larger number, but “modest” undersells the recurring cost, and dues rise with the multiplier over a lifetime.
2. Fund your preservation via life insurance. Rather than paying $200,000 (whole body) or $80,000 (neuro) in cash, you take a policy naming Alcor as beneficiary and transferring ownership to Alcor; the payout funds preservation on legal death. Alcor requires the carrier to hold an A.M. Best rating of A− or better. On price, industry rate surveys put a 20-year $250,000 term policy at roughly $28–$35 a month for a healthy 40-year-old, with the same policy roughly doubling in cost by age 50 and rising sharply again by 60 — so the commonly quoted “$40–$80 a month at 40” is above the market average for a standard-health applicant. One caveat those quotes hide: term insurance expires, and cryonics funding has to still be in force whenever you actually die. Permanence generally means whole or universal life at materially higher premiums, or re-qualifying for new coverage at an older age and worse health — budget for that, not for the term quote.
3. Execute standby instructions. Update your will and medical directives, carry the Alcor alert card, and notify Alcor immediately if hospitalised with a terminal condition so they can coordinate cooling and transport at the moment of legal death.
4. Inform your family. This is critical — your family will experience your legal death as final unless you’ve prepared them, and their cooperation during the standby window is essential. Alcor provides family resources.

The regulatory and legal foundation

Alcor is a US non-profit based in Arizona, and the legal mechanism is more specific than “it isn’t illegal.” Cryonics is not an approved or licensed medical procedure anywhere, and it is not regulated as a therapy; it can only begin after a physician or medical examiner has pronounced legal death. Alcor then takes custody of the body as an anatomical donation for research and education under the Uniform Anatomical Gift Act — Arizona’s version is A.R.S. §36-841 et seq. — the same statutory route medical schools use for donated cadavers. Legally, a patient in a dewar is human remains, not a living person with rights, which is why pre-mortem paperwork matters so much: a written donation made in advance is what prevents relatives from disposing of you otherwise.

Nor has that standing gone unchallenged. The 1988 Dora Kent coroner’s raid, the Ted Williams family dispute, and Alcor v. Richardson all went through courts, and Alcor has come out the other side. That record is meaningful — but it establishes cryonics as a lawful form of body disposition, not as a sanctioned medical treatment, and the two claims are frequently conflated in Alcor’s favour.

The transparency audit: what Alcor publishes, and why it matters

Alcor maintains a public case-reports archive — medical histories, time from cardiac arrest to cooling, vitrification outcomes, and storage data — including cases that went badly. Most life-extension organisations would bury their failures; exposing them to drive improvement is an unusually strong signal of good faith. Radical transparency about your limitations is the closest thing this field has to credibility — though it’s worth being clear that publishing honest failure reports demonstrates integrity, not that the underlying revival bet will pay off.

Frequently asked questions

Is vitrification damage reversible?
Not with current technology, and not in any laboratory. Cryoprotectant toxicity remains the acknowledged limiting factor in reversible organ cryopreservation, and no vitrified human brain has ever been rewarmed to any functional state. Alcor’s argument is that future molecular-repair technology could rebuild the preserved structures from the brain’s 3D map. Whether that technology ever exists is unknown — this is the central unproven assumption, and no one can honestly promise it.

What if the power grid fails and the liquid nitrogen runs out?
The dewars are vacuum-insulated passive vessels, so they need no electricity to stay cold — a power cut alone doesn’t warm them. (The “gravity-fed” description often repeated online is wrong: Alcor’s own engineering discussion rejects gravity-feed plumbing as too lossy and uses pumped refills instead, with the dewars boiling off roughly half to three-quarters of an inch of nitrogen a day.) By Alcor’s estimate, if liquid-nitrogen resupply stopped completely it would take more than 90 days to boil dry. The realistic failure mode is therefore not a blackout but the slow one: loss of supply, funding or institutional will over decades — which is precisely what happened at Chatsworth in 1979.

Is Alcor a cult?
The evidence doesn’t support the label: members lead diverse independent lives, there’s no charismatic leader demanding devotion, membership is contractual rather than religious, and the organisation is transparent about its science and limits. It’s a speculative bet on technology, not a faith movement — though, like any specialised community, members do form bonds around shared interest.

What’s the actual probability revival works?
No one can honestly quantify it, and Alcor doesn’t try to. It depends on unknowns — whether emulation is possible, whether molecular repair can work at scale, whether a future civilisation has the resources and interest. Any figure you’ve seen is a guess. The only defensible statement is “non-zero but unproven,” which beats burial’s structural zero by an unknown margin.

Can I change my mind after joining?
Yes. Cryopreservation is voluntary; before legal death you can withdraw at any time and cancel the policy. Once in suspension you can’t withdraw (you’re legally dead), though family could theoretically request thawing — which Alcor would try to dissuade based on your prior wishes.

The verdict: is Alcor right for you?

Consider Alcor if: you view death as a problem worth probing rather than an unquestioned ending; you can afford the life-insurance premiums without strain; you’re genuinely comfortable with speculative, unproven science; and you find Alcor’s track record, Trust structure, and transparency reassuring.

Skip Alcor if: you’ve made peace with biological finitude, or believe revival is impossible or unethical; the premiums would strain your finances; you’d rather pour every dollar into the life you’re certain you have; or you simply don’t want to bet on a future you can’t see.

The honest final logic: Alcor isn’t a guarantee of anything, and it would be wrong to call it a “mandatory” anything — it’s an unproven, long-odds insurance against permanent deletion, chosen by people for whom a small unknown chance is worth a modest premium. A preserved brain has speculative futures; a cremated one has none. For someone who has looked clearly at the uncertainty and still finds the wager worth making, it’s a coherent choice — and for someone who hasn’t, walking away with open eyes is an equally sovereign one. The value isn’t certainty. It’s deciding the biggest question yourself, instead of letting the default decide for you.

Related reading: Proton Drive Review: the logic of encrypted persistence and the data sovereignty unhack.

Where to get it: Hostinger — web hosting, VPS and domains. Affiliate link — The Unhacked may earn a small commission at no cost to you; our verdict isn’t for sale.